drugset / Trial / NCT02081391

A Study to Look at Tapentadol Oral Solution in Children and Adolescents in Pain

NCT02081391

Phase 3 Completed 216 enrolled Grünenthal GmbH Depomed · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study was to evaluate the efficacy of tapentadol oral solution, based on the total amount of supplemental opioid analgesic used over 12 hours or 24 hours after initiation of investigational medicinal product (IMP) in children and adolescents who had undergone surgery that would produce moderate to severe pain during opioid treatment.

Timeline

Start
2015-02-19
Primary completion
2019-03-03
Completion
2019-03-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Tapentadol Small molecule 0.1 mg/kg Oral
Subject Tapentadol Small molecule 0.5 mg/kg Oral
Subject Tapentadol Small molecule 1.25 mg/kg Oral

Indications

No indication recorded.